Oncolytics Biotech is trading at $0.94 (5.9% up) in pre-market, extending a volatile stretch that included a double-digit gain on July 9 followed by a pullback on July 10.
- The move appears driven by trading momentum rather than a clear fundamental catalyst, as there is no new company-specific news, earnings, or FDA updates.
- The company's most recent significant milestones remain its Q1 earnings reported on May 14, 2026, and a prior announcement regarding FDA alignment.